Taylor Ben R Insider Trades

Insider Trading History

Track insider trading activity for Taylor Ben R. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.21M 1,107,272 shares
Last Trade
May 15, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$76.1k 25,018 shares
$3.04
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.3M 1,132,290 shares
Last Trade
Apr 06, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$149k 48,028 shares
$3.11
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.49M 1,180,318 shares
Last Trade
Mar 17, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$27k 7,956 shares
$3.39
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.52M 1,188,274 shares
Last Trade
Mar 16, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$24.2k 7,075 shares
$3.42
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.54M 1,195,349 shares
Last Trade
Feb 18, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$47.4k 13,426 shares
$3.53
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.59M 1,208,775 shares
Last Trade
Feb 17, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$41.6k 11,908 shares
$3.49
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.64M 1,220,683 shares
Last Trade
Feb 06, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$45.4k 11,400 shares
$3.98
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $4.68M 1,232,083 shares
Last Trade
Feb 06, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.87M 470,533 shares
$3.98
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $2.89M 761,550 shares
Last Trade
Dec 29, 2025 Sale (Open Market)Shares sold on the open market or in a private sale.
$89.4k 21,383 shares
$4.18
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $2.98M 782,933 shares
Last Trade
Dec 15, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$30.6k 7,057 shares
$4.33
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3M 789,990 shares
Last Trade
Nov 25, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$9.15k 2,271 shares
$4.03
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.01M 792,261 shares
Last Trade
Nov 17, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$49.3k 11,908 shares
$4.14
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.06M 804,169 shares
Last Trade
Sep 15, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$34.1k 7,057 shares
$4.83
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.08M 811,226 shares
Last Trade
Aug 15, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$67.2k 11,908 shares
$5.64
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.13M 823,134 shares
Last Trade
Jun 16, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$34.7k 7,057 shares
$4.92
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.15M 830,191 shares
Last Trade
May 15, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$50.6k 11,908 shares
$4.25
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.2M 842,099 shares
Last Trade
Apr 01, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$136k 26,571 shares
$5.10
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.3M 868,670 shares
Last Trade
Mar 17, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$48.3k 7,057 shares
$6.84
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.33M 875,727 shares
Last Trade
Feb 18, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$116k 10,879 shares
$10.64
$3.80
Recursion Pharmaceuticals
Recursion Pharmaceuticals RXRX
Chief Financial Officer
Holding Value $3.37M 886,606 shares
Last Trade
Feb 03, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$47.4k 6,544 shares
$7.25
$3.80

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up